Current and future antiplatelet therapies: emphasis on preserving haemostasis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-01-03

AUTHORS

James D. McFadyen, Mathieu Schaff, Karlheinz Peter

ABSTRACT

Key PointsAntiplatelet agents form a cornerstone of therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention, as well as in the secondary prevention of cardiovascular eventsCurrently available antiplatelet agents, including cyclooxygenase 1 inhibitors, P2Y purinoreceptor 12 (P2Y12) antagonists, protease-activated receptor 1 antagonists, and glycoprotein (GP) IIb/IIIa antagonists, inhibit processes important for both thrombosis and haemostasisBleeding remains a major limitation of current therapeutic approaches, with the most intensive antithrombotic regimens associated with an increased risk of bleedingThe adverse effects of bleeding on mortality and cardiovascular outcomes might offset the benefit of potent antiplatelet strategiesExperimental work has highlighted that thrombus formation in vivo is a dynamic process; new regulators of thrombus formation and, therefore, therapeutic targets that do not impair haemostasis have been identifiedNew antiplatelet strategies, including inhibitors of phosphatidylinositol 3-kinase-β (PI3Kβ), protein disulfide-isomerase (PDI), activated GPIIb/IIIa, GPIIb/IIIa outside-in signalling, protease-activated receptors, and platelet GPVI-mediated adhesion pathways, are in preclinical and early-phase clinical trials More... »

PAGES

181-191

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/nrcardio.2017.206

DOI

http://dx.doi.org/10.1038/nrcardio.2017.206

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100157210

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29297508


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Platelets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Decision-Making", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrinolytic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemostasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Haematology, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1623.6", 
          "name": [
            "Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia", 
            "Department of Medicine, Monash University, 3800, Melbourne, Victoria, Australia", 
            "Department of Clinical Haematology, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McFadyen", 
        "givenName": "James D.", 
        "id": "sg:person.01331075632.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331075632.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1051.5", 
          "name": [
            "Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schaff", 
        "givenName": "Mathieu", 
        "id": "sg:person.0620123616.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620123616.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Heart Centre, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1623.6", 
          "name": [
            "Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia", 
            "Department of Medicine, Monash University, 3800, Melbourne, Victoria, Australia", 
            "Department of Immunology, Monash University, 3800, Melbourne, Victoria, Australia", 
            "Heart Centre, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peter", 
        "givenName": "Karlheinz", 
        "id": "sg:person.01230116350.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116350.02"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature01323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001371417", 
          "https://doi.org/10.1038/nature01323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009866371", 
          "https://doi.org/10.1038/nm1232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.1955", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029219248", 
          "https://doi.org/10.1038/nm.1955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrcardio.2011.96", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024711883", 
          "https://doi.org/10.1038/nrcardio.2011.96"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-013-1026-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030060823", 
          "https://doi.org/10.1007/s11239-013-1026-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042145879", 
          "https://doi.org/10.1038/nrd2957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature12613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007802561", 
          "https://doi.org/10.1038/nature12613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrcardio.2014.156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050770433", 
          "https://doi.org/10.1038/nrcardio.2014.156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12265-012-9435-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042021000", 
          "https://doi.org/10.1007/s12265-012-9435-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-01-03", 
    "datePublishedReg": "2018-01-03", 
    "description": "Key PointsAntiplatelet agents form a cornerstone of therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention, as well as in the secondary prevention of cardiovascular eventsCurrently available antiplatelet agents, including cyclooxygenase 1 inhibitors, P2Y purinoreceptor 12 (P2Y12) antagonists, protease-activated receptor 1 antagonists, and glycoprotein (GP) IIb/IIIa antagonists, inhibit processes important for both thrombosis and haemostasisBleeding remains a major limitation of current therapeutic approaches, with the most intensive antithrombotic regimens associated with an increased risk of bleedingThe adverse effects of bleeding on mortality and cardiovascular outcomes might offset the benefit of potent antiplatelet strategiesExperimental work has highlighted that thrombus formation in vivo is a dynamic process; new regulators of thrombus formation and, therefore, therapeutic targets that do not impair haemostasis have been identifiedNew antiplatelet strategies, including inhibitors of phosphatidylinositol 3-kinase-\u03b2 (PI3K\u03b2), protein disulfide-isomerase (PDI), activated GPIIb/IIIa, GPIIb/IIIa outside-in signalling, protease-activated receptors, and platelet GPVI-mediated adhesion pathways, are in preclinical and early-phase clinical trials", 
    "genre": "article", 
    "id": "sg:pub.10.1038/nrcardio.2017.206", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1381287", 
        "issn": [
          "1759-5002", 
          "1759-5010"
        ], 
        "name": "Nature Reviews Cardiology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "GPIIb/IIIa", 
      "protease-activated receptor-1 antagonist", 
      "thrombus formation", 
      "glycoprotein IIb/IIIa antagonists", 
      "IIb/IIIa antagonists", 
      "early phase clinical trials", 
      "future antiplatelet therapies", 
      "cornerstone of therapy", 
      "acute coronary syndrome", 
      "percutaneous coronary intervention", 
      "available antiplatelet agents", 
      "current therapeutic approaches", 
      "receptor 1 antagonist", 
      "protease-activated receptors", 
      "cyclooxygenase-1 inhibitor", 
      "antithrombotic regimens", 
      "coronary syndrome", 
      "cardiovascular outcomes", 
      "antiplatelet therapy", 
      "coronary intervention", 
      "secondary prevention", 
      "antiplatelet strategies", 
      "antiplatelet agents", 
      "clinical trials", 
      "therapeutic approaches", 
      "therapeutic target", 
      "platelet GPVI", 
      "adverse effects", 
      "inhibitor of phosphatidylinositol", 
      "antagonist", 
      "therapy", 
      "haemostasis", 
      "adhesion pathway", 
      "IIIa", 
      "inhibitors", 
      "thrombosis", 
      "regimens", 
      "patients", 
      "syndrome", 
      "agents", 
      "mortality", 
      "new regulator", 
      "trials", 
      "prevention", 
      "receptors", 
      "GPVI", 
      "intervention", 
      "outcomes", 
      "major limitation", 
      "risk", 
      "vivo", 
      "signaling", 
      "pathway", 
      "cornerstone", 
      "phosphatidylinositol", 
      "target", 
      "protein", 
      "benefits", 
      "regulator", 
      "effect", 
      "strategies", 
      "limitations", 
      "formation", 
      "emphasis", 
      "dynamic process", 
      "process", 
      "approach", 
      "work"
    ], 
    "name": "Current and future antiplatelet therapies: emphasis on preserving haemostasis", 
    "pagination": "181-191", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100157210"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/nrcardio.2017.206"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29297508"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/nrcardio.2017.206", 
      "https://app.dimensions.ai/details/publication/pub.1100157210"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_778.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/nrcardio.2017.206"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrcardio.2017.206'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrcardio.2017.206'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrcardio.2017.206'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrcardio.2017.206'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      21 PREDICATES      117 URIs      100 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/nrcardio.2017.206 schema:about N0790d9aacbda4ab4b7a133c7573268f8
2 N174a9bb81ca443d7a0f9c10561713135
3 N1c5dc97212ce4979a0cd65d310f02911
4 N3b49b234ad0b455391f26d395fc334c5
5 N3d7fec056c364ce58df217b79ed3e387
6 N74c62d953a4c404fb79bc04c6babc418
7 N816c3b844b9447f6b24d087496bd96b5
8 N94145b1c87ff4f42b2e652cb074b2884
9 N9f114245bcf74f03a7d219af6fb13d40
10 Na6030cb6c9be4d5697527052792f296f
11 Nae75ba9769e742bf811a8c3d56dad44e
12 Nd523fa2f119a48b4b071ed6228291bc3
13 Nd7edd9381da44b4586e1f22ac7ca646f
14 Nefa1dbb61d88483f9badb2d982556364
15 Nfe193d06c79244de98a25147b9d1ae59
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N347e7ec256d74e0ea9f8fd353fed13f6
19 schema:citation sg:pub.10.1007/s11239-013-1026-5
20 sg:pub.10.1007/s12265-012-9435-y
21 sg:pub.10.1038/nature01323
22 sg:pub.10.1038/nature12613
23 sg:pub.10.1038/nm.1955
24 sg:pub.10.1038/nm1232
25 sg:pub.10.1038/nrcardio.2011.96
26 sg:pub.10.1038/nrcardio.2014.156
27 sg:pub.10.1038/nrd2957
28 schema:datePublished 2018-01-03
29 schema:datePublishedReg 2018-01-03
30 schema:description Key PointsAntiplatelet agents form a cornerstone of therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention, as well as in the secondary prevention of cardiovascular eventsCurrently available antiplatelet agents, including cyclooxygenase 1 inhibitors, P2Y purinoreceptor 12 (P2Y12) antagonists, protease-activated receptor 1 antagonists, and glycoprotein (GP) IIb/IIIa antagonists, inhibit processes important for both thrombosis and haemostasisBleeding remains a major limitation of current therapeutic approaches, with the most intensive antithrombotic regimens associated with an increased risk of bleedingThe adverse effects of bleeding on mortality and cardiovascular outcomes might offset the benefit of potent antiplatelet strategiesExperimental work has highlighted that thrombus formation in vivo is a dynamic process; new regulators of thrombus formation and, therefore, therapeutic targets that do not impair haemostasis have been identifiedNew antiplatelet strategies, including inhibitors of phosphatidylinositol 3-kinase-β (PI3Kβ), protein disulfide-isomerase (PDI), activated GPIIb/IIIa, GPIIb/IIIa outside-in signalling, protease-activated receptors, and platelet GPVI-mediated adhesion pathways, are in preclinical and early-phase clinical trials
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N5b21db98a0ab4d79b440c0ac37e18af5
34 Nb97de6f142504dac9dc87241328c410d
35 sg:journal.1381287
36 schema:keywords GPIIb/IIIa
37 GPVI
38 IIIa
39 IIb/IIIa antagonists
40 acute coronary syndrome
41 adhesion pathway
42 adverse effects
43 agents
44 antagonist
45 antiplatelet agents
46 antiplatelet strategies
47 antiplatelet therapy
48 antithrombotic regimens
49 approach
50 available antiplatelet agents
51 benefits
52 cardiovascular outcomes
53 clinical trials
54 cornerstone
55 cornerstone of therapy
56 coronary intervention
57 coronary syndrome
58 current therapeutic approaches
59 cyclooxygenase-1 inhibitor
60 dynamic process
61 early phase clinical trials
62 effect
63 emphasis
64 formation
65 future antiplatelet therapies
66 glycoprotein IIb/IIIa antagonists
67 haemostasis
68 inhibitor of phosphatidylinositol
69 inhibitors
70 intervention
71 limitations
72 major limitation
73 mortality
74 new regulator
75 outcomes
76 pathway
77 patients
78 percutaneous coronary intervention
79 phosphatidylinositol
80 platelet GPVI
81 prevention
82 process
83 protease-activated receptor-1 antagonist
84 protease-activated receptors
85 protein
86 receptor 1 antagonist
87 receptors
88 regimens
89 regulator
90 risk
91 secondary prevention
92 signaling
93 strategies
94 syndrome
95 target
96 therapeutic approaches
97 therapeutic target
98 therapy
99 thrombosis
100 thrombus formation
101 trials
102 vivo
103 work
104 schema:name Current and future antiplatelet therapies: emphasis on preserving haemostasis
105 schema:pagination 181-191
106 schema:productId N60108559aa99498198d0b5830e6f930b
107 Naa7379cb8c27434da5d6f659cc329721
108 Nb866733332e7419c96e32f3a037f1dd1
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100157210
110 https://doi.org/10.1038/nrcardio.2017.206
111 schema:sdDatePublished 2022-12-01T06:38
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Nefe05d9bf1fb46a5ab51591183f1ad6b
114 schema:url https://doi.org/10.1038/nrcardio.2017.206
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0790d9aacbda4ab4b7a133c7573268f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Risk Assessment
120 rdf:type schema:DefinedTerm
121 N174a9bb81ca443d7a0f9c10561713135 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Hemostasis
123 rdf:type schema:DefinedTerm
124 N1944e25ac2424add9bf77c5da0316fc9 rdf:first sg:person.0620123616.14
125 rdf:rest N1fd5a79a10bc454592c46bf95af4d3f3
126 N1c5dc97212ce4979a0cd65d310f02911 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Hemorrhage
128 rdf:type schema:DefinedTerm
129 N1fd5a79a10bc454592c46bf95af4d3f3 rdf:first sg:person.01230116350.02
130 rdf:rest rdf:nil
131 N347e7ec256d74e0ea9f8fd353fed13f6 rdf:first sg:person.01331075632.59
132 rdf:rest N1944e25ac2424add9bf77c5da0316fc9
133 N3b49b234ad0b455391f26d395fc334c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Fibrinolytic Agents
135 rdf:type schema:DefinedTerm
136 N3d7fec056c364ce58df217b79ed3e387 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Molecular Targeted Therapy
138 rdf:type schema:DefinedTerm
139 N5b21db98a0ab4d79b440c0ac37e18af5 schema:volumeNumber 15
140 rdf:type schema:PublicationVolume
141 N60108559aa99498198d0b5830e6f930b schema:name pubmed_id
142 schema:value 29297508
143 rdf:type schema:PropertyValue
144 N74c62d953a4c404fb79bc04c6babc418 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Patient Selection
146 rdf:type schema:DefinedTerm
147 N816c3b844b9447f6b24d087496bd96b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Thrombosis
149 rdf:type schema:DefinedTerm
150 N94145b1c87ff4f42b2e652cb074b2884 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Blood Platelets
152 rdf:type schema:DefinedTerm
153 N9f114245bcf74f03a7d219af6fb13d40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Clinical Decision-Making
155 rdf:type schema:DefinedTerm
156 Na6030cb6c9be4d5697527052792f296f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Risk Factors
158 rdf:type schema:DefinedTerm
159 Naa7379cb8c27434da5d6f659cc329721 schema:name dimensions_id
160 schema:value pub.1100157210
161 rdf:type schema:PropertyValue
162 Nae75ba9769e742bf811a8c3d56dad44e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Nb866733332e7419c96e32f3a037f1dd1 schema:name doi
166 schema:value 10.1038/nrcardio.2017.206
167 rdf:type schema:PropertyValue
168 Nb97de6f142504dac9dc87241328c410d schema:issueNumber 3
169 rdf:type schema:PublicationIssue
170 Nd523fa2f119a48b4b071ed6228291bc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Animals
172 rdf:type schema:DefinedTerm
173 Nd7edd9381da44b4586e1f22ac7ca646f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Treatment Outcome
175 rdf:type schema:DefinedTerm
176 Nefa1dbb61d88483f9badb2d982556364 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Drug Design
178 rdf:type schema:DefinedTerm
179 Nefe05d9bf1fb46a5ab51591183f1ad6b schema:name Springer Nature - SN SciGraph project
180 rdf:type schema:Organization
181 Nfe193d06c79244de98a25147b9d1ae59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Platelet Aggregation Inhibitors
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
188 schema:name Cardiorespiratory Medicine and Haematology
189 rdf:type schema:DefinedTerm
190 sg:journal.1381287 schema:issn 1759-5002
191 1759-5010
192 schema:name Nature Reviews Cardiology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01230116350.02 schema:affiliation grid-institutes:grid.1623.6
196 schema:familyName Peter
197 schema:givenName Karlheinz
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116350.02
199 rdf:type schema:Person
200 sg:person.01331075632.59 schema:affiliation grid-institutes:grid.1623.6
201 schema:familyName McFadyen
202 schema:givenName James D.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331075632.59
204 rdf:type schema:Person
205 sg:person.0620123616.14 schema:affiliation grid-institutes:grid.1051.5
206 schema:familyName Schaff
207 schema:givenName Mathieu
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620123616.14
209 rdf:type schema:Person
210 sg:pub.10.1007/s11239-013-1026-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030060823
211 https://doi.org/10.1007/s11239-013-1026-5
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s12265-012-9435-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1042021000
214 https://doi.org/10.1007/s12265-012-9435-y
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/nature01323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001371417
217 https://doi.org/10.1038/nature01323
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/nature12613 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007802561
220 https://doi.org/10.1038/nature12613
221 rdf:type schema:CreativeWork
222 sg:pub.10.1038/nm.1955 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029219248
223 https://doi.org/10.1038/nm.1955
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/nm1232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009866371
226 https://doi.org/10.1038/nm1232
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/nrcardio.2011.96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024711883
229 https://doi.org/10.1038/nrcardio.2011.96
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/nrcardio.2014.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050770433
232 https://doi.org/10.1038/nrcardio.2014.156
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/nrd2957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042145879
235 https://doi.org/10.1038/nrd2957
236 rdf:type schema:CreativeWork
237 grid-institutes:grid.1051.5 schema:alternateName Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia
238 schema:name Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia
239 rdf:type schema:Organization
240 grid-institutes:grid.1623.6 schema:alternateName Department of Clinical Haematology, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia
241 Heart Centre, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia
242 schema:name Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, 75 Commercial Road, PO Box 6492, 3004, Melbourne, Victoria, Australia
243 Department of Clinical Haematology, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia
244 Department of Immunology, Monash University, 3800, Melbourne, Victoria, Australia
245 Department of Medicine, Monash University, 3800, Melbourne, Victoria, Australia
246 Heart Centre, Alfred Hospital, 55 Commercial Road, 3004, Melbourne, Victoria, Australia
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...